Skip to content
Search AI Powered

Latest Stories

Rising drug taxes may necessitate ICBs to secure an additional £37 million annually, says BGMA    

The spiralling tax rates will raise NHS costs and affect pharmacy contractors cashflow

The British Generic Manufacturers Association (BGMA) has warned that England's 42 integrated care boards (ICBs) may need to allocate an extra £37 million from their budgets annually for the next five years due to the spiralling tax rates.


The government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) rebate rate increased more than five-fold in the past two years, the BGMA said in its white paper released on Monday (October 30).

The report, conducted by consultancy firm Conclusio in consultation with local NHS leaders, examined the potential effects of the VPAS on ICB budgets.

BGMA said that due to the elevated VPAS rate, each ICB in England will experience significant increases in expenses for branded generics and biosimilars annually – a consequence of reduced competition.

In many cases, this increase will wipe away any projected surplus. While sizes of ICBs vary, the report calculated that £37 million is roughly 10-20 per cent of ICBs entire pharmaceutical spend.

For the current VPAS period, the allowable growth rate is set at 2 per cent per annum and the payment percentage (levy) in 2023 is 26.5 per cent, which is over five times what it was just two years ago.

“The VPAS rate has spiralled, rocketing to 26.5 per cent with every chance it could go higher in the future,” said Mark Samuels, chief executive of the BGMA. “For off-patent medicines such as branded generics and biosimilars, this is an unsustainable position as companies cannot afford to keep absorbing an increasing rate on top of having their prices constrained by competition.”

Meanwhile, the negotiations between DHSC, NHSE and ABPI are currently underway for the next VPAs, which will run from 2024 to 2028. Presently, nearly half the current scheme is made up of branded generics and biosimilars, which face a double whammy of having their prices constrained by competition as well as having to pay the increasing VPAS levy on their revenues.

Samuels said that manufacturers are already having to make very difficult decisions as to whether they can continue to maintain supply of products. “More than 85 biological medicines will lose their exclusivity in the next five years including blockbuster products such as cancer medicine Keytruda and wet macular product Eylea,” he said.

“These represent a great savings opportunity to the NHS, but they won’t fulfil their savings potential if competition is reduced because fewer companies enter the market,” Samuels added. “The reduced savings will undoubtedly be felt at the frontline of delivery and is likely to add even further strain on already thinly stretched local NHS budgets.”

As well as a reduction in savings, the report also states that an increase in medicines shortages is inevitable as a result of a more volatile market stemming from fewer suppliers, potentially less stock being earmarked for the UK and product withdrawals.

This is likely to not only raise prices for the NHS, but also affect the cashflow of pharmacy contractors. Pharmacists may spend up to a third of their working week addressing shortages instead of assisting the NHS in providing patient advice and prescribing specific treatments.

According to BGMA, limiting access to preventative treatments could lead to reduced management of chronic conditions and an increased likelihood of costly acute hospital care, potentially resulting in poorer patient outcomes.

BGMA recently backed the UK government’s proposed changes to the Statutory Scheme for branded medicines, which includes a ‘Life Cycle Adjustment’ (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets.

More For You

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Prakash Patel was speaking at a panel discussion at the Sigma Conference

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Pharmacists need to be a part of integrated care boards (ICB) to stop GPs from monopolising services based on their needs rather than the needs of the patient, according to Prakash Patel, Community Pharmacy Engaland (CPE) representative for North London.

“The evolution of the NHS should mean there can be no decision of pharmacy without pharmacist,” Patel told delegates at the Sigma Pharmacy Conference in Baku, Azerbaijan on Tuesday.

Keep ReadingShow less
David Webb
David Webb, NHS England's Chief Pharmaceutical Officer
David Webb, NHS England's Chief Pharmaceutical Officer

Sigma Conference: "Community pharmacy ready to make a profound contribution to 10 Year Health Plan," says David Webb

A national community pharmacy prescribing service remains a long-term goal of the government, according to NHS chief pharmaceutical officer, David Webb.

The Labour Party in its election manifesto last year said it would “create a Community Pharmacist Prescribing Service, granting more pharmacists independent prescribing rights”.

Keep ReadingShow less
Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less